In contrast to other subtypes of ALL, including the more frequent pediatric patients, the incidence of the Philadelphia chromosome (Ph+)-positive B-ALL (BCR::ABL+) increases with age in up to 50% of patients and was considered to signal a poor prognosis before tyrosine kinase inhibitors (TKI) targeting BCR::ABL were combined with classical backbone chemotherapy [2,3]. This evidence concerns the gene ABL1 and precursor B-cell acute lymphoblastic leukemia.